Literature DB >> 25458182

Cell-based peptide screening to access the undruggable target space.

Hanjo Hennemann1, Sabine Wirths2, Claudia Carl2.   

Abstract

Only 20-30% of drug target proteins can be accessed by common drug classes, like small molecules or therapeutic antibodies. The vast majority of the remaining proteins are considered "undruggable" and include drug target proteins, like transcription factors, scaffold or adapter proteins, which play important roles in disease. However over the last years innovative compound classes including nucleotide derived drugs (e.g. siRNA, antisense), macrocyclic compounds and cell-permeable peptides matured significantly and hold now the potential to modulate these hard to access target proteins for therapeutic use. This article will focus on the discovery of cell-permeable peptides and discuss intracellular screening systems for peptides, which yield highly relevant peptides, because peptide selection takes place in eukaryotic cells, under conditions, which are very similar to the later therapeutic use.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Keywords:  Cell-permeable peptides; Drug; Drug discovery; Library; Peptide screening; Screening; Therapeutics; Undruggable targets

Mesh:

Substances:

Year:  2014        PMID: 25458182     DOI: 10.1016/j.ejmech.2014.10.038

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  3 in total

Review 1.  Recent advances in the biosynthesis of RiPPs from multicore-containing precursor peptides.

Authors:  Garret M Rubin; Yousong Ding
Journal:  J Ind Microbiol Biotechnol       Date:  2020-07-02       Impact factor: 3.346

Review 2.  Rational Design of Constrained Peptides as Protein Interface Inhibitors.

Authors:  Ramachandran Murali; Hongtao Zhang; Zheng Cai; Lian Lam; Mark Greene
Journal:  Antibodies (Basel)       Date:  2021-08-16

Review 3.  Systematic Targeting of Protein-Protein Interactions.

Authors:  Ashley E Modell; Sarah L Blosser; Paramjit S Arora
Journal:  Trends Pharmacol Sci       Date:  2016-06-04       Impact factor: 14.819

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.